Author pages are created from data sourced from our academic publisher partnerships and public sources.
Share This Author
Biomarkers Predicting Clinical Outcome of Epidermal Growth Factor Receptor–Targeted Therapy in Metastatic Colorectal Cancer
- S. Siena, A. Sartore-Bianchi, F. Di Nicolantonio, J. Balfour, A. Bardelli
- Journal of the National Cancer Institute
- 7 October 2009
The use of KRAS mutations as a selection biomarker for anti-EGFR monoclonal antibody (eg, panitumumab or cetuximab) treatment is the first major step toward individualized treatment for patients with metastatic colorectal cancer. Expand
Ciprofloxacin. An updated review of its pharmacology, therapeutic efficacy and tolerability.
Ciprofloxacin has retained its excellent activity against most Gram-negative bacteria, and fulfilled its potential as an important antibacterial drug in the treatment of a wide range of infections. Expand
Lornoxicam. A review of its pharmacology and therapeutic potential in the management of painful and inflammatory conditions.
Preliminary clinical trials suggest that lornoxicam is as effective as the opioid analgesics morphine, pethidine (meperidine) and tramadol in relieving postoperative pain following gynaecological or orthopaedic surgery, and aseffective as other NSAIDs after oral surgery. Expand
Fosfomycin tromethamine. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy as a single-dose oral treatment for acute uncomplicated lower urinary tract…
Fosfomycin tromethamine achieves high clinical and bacteriological cure rates in patients with acute uncomplicated lower urinary tract infection and is well tolerated, with a low incidence of adverse events. Expand
Fenofibrate. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic use in dyslipidaemia.
Fenofibrates offers an effective and well tolerated alternative to clofibrate or other fibric acid derivatives, but its relative efficacy and tolerability compared with other types of lipid-lowering drugs, and its effect on cardiovascular morbidity and mortality, remain to be clarified. Expand
Terbinafine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in superficial mycoses.
Although further research is required to establish the efficacy of terbinafine in comparison with other available therapies, as well as to fully clarify its tolerability profile, the early results obtained with terbINAfine in superficial fungal infections are very encouraging. Expand
Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Pooled clinical trial data suggest that glimepiride may have a lower incidence of hypoglycaemia than glibenclamide, particularly in the first month of treatment, and its possible tolerability advantages and use in combination with other oral antidiabetic drugs require further study. Expand
Azithromycin. A review of its use in paediatric infectious diseases.
Azithromycin is an effective and well tolerated alternative to first-line agents in the treatment of respiratory tract, skin and soft tissue infections in children, offerring the convenience of a short, once-daily regimen. Expand
Mitoxantrone. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in the chemotherapy of cancer.
Mitoxantrone is an effective and better tolerated alternative to the anthracyclines in most haematological malignancies, in breast cancer and in advanced hepatic or ovarian carcinoma, and synergy with other antineoplastic drugs has been demonstrated in murine tumour models. Expand
Acarbose : An Update of its Pharmacology and Therapeutic Use in Diabetes Mellitus.
Clinical trials have demonstrated that acarbose generally improves glycaemic control in patients with non-insulin-dependent diabetes mellitus (NIDDM) managed with diet alone, or with other antidiabetic therapy, as evidenced by decreased postprandial plasma glucose and glycosylated haemoglobin levels. Expand